ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 959

A Novel Image Analysis Program, “CytoSkaler”, Demonstrates That Anti-Vimentin Antibody Affinity Maturation in Lupus Tubulointerstitial Nephritis Also Results in More Selective Antigen Targeting

Andrew Kinloch1, Aazam Mohsin 1, Yuta Asano 1, Carole Henry 1, Nirit Mor Vaknin 2, Maureen Legendre 2, Patrick Wilson 1, David Markovitz 2 and Marcus Clark 1, 1University of Chicago, Chicago, IL, 2University of Michigan, Ann Arbor, MI

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: autoantibodies, B cell targeting and inflammation, Imaging, Lupus nephritis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: B Cell Biology & Targets In Autoimmune & Inflammatory Disease Poster

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Vimentin is a dominant target of B-cells selected in lupus tubulointerstial inflammation (TII), a predictor of renal failure. The origins of anti-vimentin antibodies (AVA) are unknown. Technologies quantifying specific antigenic targeting do not exist. Objectives:1 Characterize reactivities of germline BCR precursors of TII AVAs; 2 Develop software to quantify mAb reactivity with subcellular regions of cultured cells and tissue; 3 Quantify selectivity of mAbs for vimentin vs other cellular antigens; 4 Determine somatic hypermutations (SHMs) influential in Vimentin selectivity.

Methods: 10 human IgG1 AVA mAbs (from 6 TII patients) in selected (sel) and germ-line reverted (rev) forms, and 21 mAbs from naïve healthy B-cells were generated. Recombinant human vimentin (native and citrullinated) reactivity was assayed by ELISA. HEp-2 cells were co-stained with TII AVAs (sel and rev) and subcellular markers (nuclear [Hoechst], vimentin [mAb V9] and cytoplasm [mAb eno-1]), and imaged by multicolor immunofluorescence laser scanning confocal microscopy. Single amino acid variants of TII mAbs “PB4” (n=16) and “PB5” (n=11), representing single SHM reversions were also assayed. Lupus TII tissue was co-stained with novel FLAG-tagged variants of PB4 and PB5 (sel and rev). Mean pixel intensity (MPI) was a measure of magnitude of human mAb reactivity. Vimentin selectivity was quantified by co-variance of binding (Pearson Correlation coefficient of MPI with anti-vimentin channel), or ratio of MPI of vimentin positive : other respective subcellular region. A machine learned software (“CytoSkaler”) was developed to identify individual cultured cells, and subcellular areas, allowing measurement of human mAb reactivities (MPIs) with subcellular regions. CytoSkaler was also used for quantifying reactivity with subcellular regions of TII tissue.

Results: 9/10 reverted TII AVA mAbs had reduced vimentin reactivities by ELISA, comparable to those of naïve healthy B-cell derived mAbs. All TII mAbs had lower reactivities with citrullinated antigen. CytoSkaler yielded highly accurate cell segmentation estimations (accuracy =0.97, intersection of union =0.96), allowing high throughput quantification of human mAb reactivities with subcellular regions. Typically, CytoSkaler demonstrated progression from low magnitude, broad cellular reactivity at germline, to high preference, and magnitude of reactivity, for vimentin positive regions following affinity maturation (i.e “PB4”). MAb PB5 was unique, maturing from a germline precursor with a speckled nuclear pattern and purified histone reactivity. Staining patterns observed with TII tissue using Flag-PB4 and -PB5 matched those generated with HEp-2 cells. Reactivity of PB4 with vimentin was due to a combination of multiple SHMs. In PB5, S36D reversion was responsible for nuclear (Histone) reactivity and G55D lost vimentin reactivity.

Conclusion: From low reactivities comparable to naïve healthy B-cells, or Histone reactivity, TII AVAs gain both affinity and selectivity for vimentin. We have developed image analysis software for quantifying mAb selectivity for candidate antigens, and a flag human IgG1 mAb construct enabling analysis of human tissue rich in IgG.


Disclosure: A. Kinloch, None; A. Mohsin, None; Y. Asano, None; C. Henry, None; N. Mor Vaknin, None; M. Legendre, None; P. Wilson, None; D. Markovitz, None; M. Clark, None.

To cite this abstract in AMA style:

Kinloch A, Mohsin A, Asano Y, Henry C, Mor Vaknin N, Legendre M, Wilson P, Markovitz D, Clark M. A Novel Image Analysis Program, “CytoSkaler”, Demonstrates That Anti-Vimentin Antibody Affinity Maturation in Lupus Tubulointerstitial Nephritis Also Results in More Selective Antigen Targeting [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/a-novel-image-analysis-program-cytoskaler-demonstrates-that-anti-vimentin-antibody-affinity-maturation-in-lupus-tubulointerstitial-nephritis-also-results-in-more-selective-antigen/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-novel-image-analysis-program-cytoskaler-demonstrates-that-anti-vimentin-antibody-affinity-maturation-in-lupus-tubulointerstitial-nephritis-also-results-in-more-selective-antigen/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology